Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Research
Biotech
Basilea opts not to take MRSA antibiotic into clinic
Basilea has cited its “stringent risk-return criteria” as a reason for not taking up its option to bring a MRSA antibiotic into clinical development.
James Waldron
Feb 18, 2025 4:08am
Trump administration lets go of ARPA-H director
Feb 14, 2025 4:45pm
Conduit taps Charles River to build AZ asset’s autoimmune cred
Feb 13, 2025 12:51pm
Oligonucleotide stops gene expansion driving Huntington's: study
Feb 12, 2025 2:00pm
Judge puts nationwide hold on NIH grant change
Feb 12, 2025 10:08am
UPDATE: Judge temporarily blocks NIH grant changes in 22 states
Feb 10, 2025 11:30am